• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

From NAFLD to MAFLD: when pathophysiology succeeds.

作者信息

Tilg Herbert, Effenberger Maria

机构信息

Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria.

出版信息

Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):387-388. doi: 10.1038/s41575-020-0316-6. Epub 2020 May 27.

DOI:10.1038/s41575-020-0316-6
PMID:32461575
Abstract
摘要

相似文献

1
From NAFLD to MAFLD: when pathophysiology succeeds.从非酒精性脂肪性肝病到代谢相关脂肪性肝病：病理生理学的成功转变
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):387-388. doi: 10.1038/s41575-020-0316-6. Epub 2020 May 27.
2
From NAFLD to MAFLD: Nurse and allied health perspective.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：护士及相关健康专业人员的视角
Liver Int. 2021 Apr;41(4):683-691. doi: 10.1111/liv.14788. Epub 2021 Feb 2.
3
What's in a name? Renaming 'NAFLD' to 'MAFLD'.名字里有什么？将“非酒精性脂肪性肝病”重新命名为“代谢功能障碍相关脂肪性肝病” 。 （备注：MAFLD全称为Metabolic Dysfunction-Associated Fatty Liver Disease ，直译为代谢功能障碍相关脂肪性肝病 ，是对NAFLD（Non-alcoholic Fatty Liver Disease，非酒精性脂肪性肝病）的重新命名 。这里如果仅按字面意思翻译，可能不太能理解其背景含义，补充了备注供你参考。）
Liver Int. 2020 Jun;40(6):1254-1261. doi: 10.1111/liv.14478. Epub 2020 Apr 28.
4
[From NAFLD to MAFLD].[从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病]
Nihon Shokakibyo Gakkai Zasshi. 2021;118(9):805-814. doi: 10.11405/nisshoshi.118.805.
5
Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.回复：关于“代谢相关脂肪性肝病的新定义：一项国际专家共识声明”的通信：代谢相关脂肪性肝病（MAFLD）：从概念到实践。
J Hepatol. 2020 Nov;73(5):1268-1269. doi: 10.1016/j.jhep.2020.06.036. Epub 2020 Aug 13.
6
Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world.对《现实世界中MAFLD与NAFLD诊断标准的比较》的回应
Liver Int. 2020 Dec;40(12):3145. doi: 10.1111/liv.14664.
7
Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data.“真实世界”数据中MAFLD与NAFLD诊断标准的一致性。
Liver Int. 2020 Nov;40(11):2879-2880. doi: 10.1111/liv.14623.
8
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.拉丁美洲肝脏研究学会（ALEH）关于重新定义脂肪肝疾病的立场声明。
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):65-72. doi: 10.1016/S2468-1253(20)30340-X. Epub 2020 Nov 9.
9
Sarcopenia and fatty liver disease.肌肉减少症与脂肪肝。
Hepatol Int. 2019 Nov;13(6):674-687. doi: 10.1007/s12072-019-09996-7. Epub 2019 Nov 8.
10
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.代谢相关脂肪性肝病的命名与定义：中东和北非地区的共识
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):57-64. doi: 10.1016/S2468-1253(20)30213-2. Epub 2020 Nov 9.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病（MASLD）：肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Naringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies.柚皮苷和柚皮素对肝脏健康的影响：分子和表观遗传机制及新兴治疗策略综述
Antioxidants (Basel). 2025 Aug 10;14(8):979. doi: 10.3390/antiox14080979.
3
Development and validation of a non-invasive prediction model for identifying high-risk children with metabolic dysfunction-associated fatty liver disease.

本文引用的文献

1
Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers.欧洲成年人杂合子或纯合子 AAT Pi∗Z 变异（Pi∗MZ 与 Pi∗ZZ 基因型）与非携带者的肝脏表型。
Gastroenterology. 2020 Aug;159(2):534-548.e11. doi: 10.1053/j.gastro.2020.04.058. Epub 2020 May 4.
2
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义：国际专家共识声明。
J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.
3
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
用于识别代谢功能障碍相关脂肪性肝病高危儿童的非侵入性预测模型的开发与验证
Front Pediatr. 2025 Aug 6;13:1625864. doi: 10.3389/fped.2025.1625864. eCollection 2025.
4
Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial.恩格列净治疗非糖尿病性脂肪肝患者的疗效：一项随机对照试验。
J Taibah Univ Med Sci. 2025 Aug 7;20(4):525-532. doi: 10.1016/j.jtumed.2025.07.008. eCollection 2025 Aug.
5
Silybin inhibits succinate production and secretion in hepatocytes to reverse liver fibrosis.水飞蓟宾抑制肝细胞中琥珀酸的产生和分泌以逆转肝纤维化。
Arch Pharm Res. 2025 Aug;48(7-8):782-797. doi: 10.1007/s12272-025-01560-2. Epub 2025 Jul 30.
6
MAFLD was more easily diagnosed than NAFLD in liver transplant recipients with abnormal liver function.在肝功能异常的肝移植受者中，MAFLD比NAFLD更容易诊断。
ILIVER. 2022 Sep 20;1(3):194-198. doi: 10.1016/j.iliver.2022.09.001. eCollection 2022 Sep.
7
Association between oxidative stress and metabolic-associated fatty liver disease in the US population.美国人群中氧化应激与代谢相关脂肪性肝病之间的关联。
Sci Rep. 2025 Jul 1;15(1):21352. doi: 10.1038/s41598-025-05044-7.
8
Modulation of liver lipid metabolic pathways by central nervous system ER stress.中枢神经系统内质网应激对肝脏脂质代谢途径的调节
Am J Physiol Endocrinol Metab. 2025 Jun 1;328(6):E833-E844. doi: 10.1152/ajpendo.00392.2024. Epub 2025 Apr 22.
9
Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity.晚期肺癌炎症指数：肝脂肪变性和纤维化严重程度的关键预测指标。
BMC Gastroenterol. 2025 Feb 24;25(1):106. doi: 10.1186/s12876-024-03544-w.
10
Dietary Inflammatory index and its association with fatty liver disease: a study in obese and non-obese populations.饮食炎症指数及其与脂肪肝疾病的关联：一项针对肥胖和非肥胖人群的研究。
BMC Gastroenterol. 2025 Feb 21;25(1):102. doi: 10.1186/s12876-024-03585-1.
非酒精性脂肪性肝炎：梅奥诊所对一种此前未命名疾病的诊疗经验
Mayo Clin Proc. 1980 Jul;55(7):434-8.